Drug intelligence / Profile preview

nab-paclitaxel + bleomycin + cisplatin + carboplatin

Development stage
Preclinical
Lead developer
Bristol Myers Squibb
Modality
Small Molecules
Administration
Intravenous, Intramuscular, Subcutaneous
01

Overview

This is a combination chemotherapy regimen consisting of four cytotoxic agents: **nab-Paclitaxel** is a nanoparticle, albumin-bound formulation of paclitaxel, a taxane that stabilizes microtubules and inhibits cell division. **Bleomycin** is an antitumor antibiotic that induces DNA strand breaks via free radical formation. **Cisplatin** and **carboplatin** are platinum-based compounds that cause DNA crosslinking and apoptosis. This combination brings together multiple mechanisms to maximize cytotoxicity against cancer cells by targeting different aspects of cell division and DNA integrity. Such combinations are studied for synergistic effects in various cancers, including lung, ovarian, breast, and others[1][4][8]. The specific four-drug combination is not standard but components have been used together or in sequence in clinical research settings.

Other names
paclitaxel albumin-stabilized nanoparticle formulation
02

Targets

DNATUBB (Tubulin (alpha and beta subunits))

Beyond the preview

Go deeper on nab-paclitaxel + bleomycin + cisplatin + carboplatin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on nab-paclitaxel + bleomycin + cisplatin + carboplatin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call